Whole genome sequencing for drug resistance determination in .
Shaheed V Omar, Lavania Joseph, Halima M Said, Farzana Ismail, Nabila Ismail, Thabisile L Gwala, Nazir A Ismail
Author Information
Shaheed V Omar: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Lavania Joseph: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Halima M Said: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Farzana Ismail: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Nabila Ismail: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Thabisile L Gwala: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
Nazir A Ismail: Centre for Tuberculosis, World Health Organization TB Supranational Reference Laboratory Network, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. ORCID
South Africa remains challenged with a high tuberculosis burden accompanied by an increase in drug resistant cases. We assessed the use of the Illumina MiSeq, a next-generation sequencing platform for whole genome sequencing, followed by bioinformatic analysis using a commercial software package to determine resistance to selected drugs used for treatment in our setting. Whole genome sequencing shows potential as a diagnostic platform for the detection of drug resistance in with the provision of information for several drugs simultaneously.
References
Int J Tuberc Lung Dis. 2006 Jul;10(7):802-7
[PMID: 16848344]